Robot Pills: A Game-Changer In Drug Delivery, With Potential Stock Upside
Portfolio Pulse from Benzinga Neuro
Early-stage drug delivery companies are developing 'robot pills' that could transform the pharmaceutical industry. Companies like Rani Therapeutics (NASDAQ:RANI) and Biora Therapeutics (NASDAQ:BIOR) are leading in this area. Despite a 36% decline in Rani's share price in 2023, Canaccord Genuity analyst Edward Nash rates Rani shares a buy, with a $26 price target, implying a 568% upside. Biora, valued at $41 million, has an average price target of $34, over 1,000% above its closing price.
September 04, 2023 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics is also developing 'robot pills' for drug delivery. The company, valued at $41 million, has an average price target of $34, over 1,000% above its closing price.
Biora Therapeutics is directly involved in the development of 'robot pills', a potentially transformative technology in the pharmaceutical industry. The company has a strong price target, suggesting significant potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Rani Therapeutics is developing 'robot pills' for drug delivery. Despite a 36% decline in its share price in 2023, it has a $26 price target, implying a 568% upside.
Rani Therapeutics is directly involved in the development of 'robot pills', a potentially transformative technology in the pharmaceutical industry. Despite a recent decline in its share price, the company has a strong price target, suggesting significant potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100